Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adenosine kinase inhibitors.

E A Kowaluk1, S S Bhagwat, M F Jarvis

  • 1Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA.

Current Pharmaceutical Design
|April 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Novel β-Lactam Enhancer Zidebactam Augments the <i>In Vivo</i> Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung <i>Acinetobacter baumannii</i> Infection Model.

Antimicrobial agents and chemotherapy·2019
Same author

A selective α2 B adrenoceptor agonist (A-1262543) and duloxetine modulate nociceptive neurones in the medial prefrontal cortex, but not in the spinal cord of neuropathic rats.

European journal of pain (London, England)·2014
Same author

The Concise Guide to PHARMACOLOGY 2013/14: overview.

British journal of pharmacology·2014
Same author

Spinal microglial activation in rat models of neuropathic and osteoarthritic pain: an autoradiographic study using [3H]PK11195.

European journal of pain (London, England)·2012
Same author

Elevated temperatures alter TRPV1 agonist-evoked excitability of dorsal root ganglion neurons.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2008
Same author

Nucleotides and their receptors in the nervous system. 1-2 August 1998, Leipzig, Germany.

IDrugs : the investigational drugs journal·2008
Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026
Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026
Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026
Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026
Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
See all related articles

Adenosine kinase (AK) inhibitors selectively increase protective adenosine levels at injury sites. This approach shows promise for treating neurological and inflammatory conditions with fewer side effects than direct receptor agonists.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Neuroscience

Background:

  • Adenosine (ADO) is a key signaling molecule that reduces cell excitability during stress and trauma.
  • ADO's effects are mediated by cell-surface receptors, influencing ion flux and neurotransmitter release.
  • Adenosine kinase (AK) regulates intracellular and extracellular ADO levels.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting Adenosine Kinase (AK).
  • To explore AK inhibition as a method to selectively enhance endogenous adenosine's protective effects.
  • To evaluate AK inhibitors in preclinical models of various diseases.

Main Methods:

  • Development of specific Adenosine Kinase (AK) inhibitors based on adenosine.
  • Testing AK inhibitors in in vitro and in vivo models.

Related Experiment Videos

  • Comparison of AK inhibitors with other adenosine-modulating strategies and direct receptor agonists.

    • Main Results:

    • AK inhibition effectively increases extracellular ADO concentrations in a tissue-specific manner.
    • AK inhibitors demonstrated efficacy in preclinical models of epilepsy, ischemia, pain, and inflammation.
    • AK inhibitors showed superior efficacy and reduced side-effect liabilities compared to direct adenosine receptor agonists.

    Conclusions:

    • AK inhibition is a promising strategy to enhance protective adenosine signaling during tissue trauma.
    • AK inhibitors may offer therapeutic benefits for central and peripheral diseases involving cellular trauma and inflammation.
    • Clinical trials are ongoing to assess AK inhibitors for seizure disorders and pain management.